It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Impel Pharmaceuticals Inc. (IMPL) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.09, or -11.25%, to $0.71. The Impel Pharmaceuticals Inc. has recorded 346,114 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache Society.
Impel Pharmaceuticals Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $0.80 and fluctuated between $1.1199 as its day high and $0.5034 as its day low. The current market capitalization of Impel Pharmaceuticals Inc. is $17.30M. A total of 36.49 million shares were traded on the day, compared to an average of 903.21K shares.
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, IMPL has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 1 BUYs and 1 SELLs from insiders. Insiders purchased 10,571 shares during that period but sold 3,627.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for IMPL in the last 3 months, the mean price target is $40.00 with high estimates of $40.00 and low estimates of $40.00. In terms of 52-week highs and lows, IMPL has a high of $7.69 and a low of $0.28.
As of this writing, IMPL has an earnings estimate of -$0.36 per share for the current quarter. EPS was calculated based on a consensus of 1 estimates, with a high estimate of -$0.36 per share and a lower estimate of -$0.36. The company reported an EPS of -$1.27 in the last quarter, which was -41.10% lower than expectations of -$0.9.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. IMPL’s latest balance sheet shows that the firm has $88.21M in Cash & Short Term Investments as of fiscal 2021. There were $29.45M in debt and $15.95M in liabilities at the time. Its Book Value Per Share was -$3.33, while its Total Shareholder’s Equity was $52.51M.
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for IMPL is Buy with a score of 5.00.